免疫疗法
T细胞受体
癌症研究
实体瘤
癌症免疫疗法
医学
T细胞
免疫学
免疫系统
内科学
癌症
作者
Yikai Zhang,Zhipeng Liu,Wei Wei,Yangqiu Li
标识
DOI:10.1186/s40164-022-00291-0
摘要
T cell immunotherapy remains an attractive approach for cancer immunotherapy. T cell immunotherapy mainly employs chimeric antigen receptor (CAR)- and T cell receptor (TCR)-engineered T cells. CAR-T cell therapy has been an essential breakthrough in treating hematological malignancies. TCR-T cells can recognize antigens expressed both on cell surfaces and in intracellular compartments. Although TCR-T cells have not been approved for clinical application, a number of clinical trials have been performed, particularly for solid tumors. In this article, we summarized current TCR-T cell advances and their potential advantages for solid tumor immunotherapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI